Overview

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy (FOX)

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.
Phase:
Phase 2
Details
Lead Sponsor:
Edgewise Therapeutics, Inc.